Arrowhead Selected to Present at Global Crown Capital’s Nanotechnology Investment Conference
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (Nasdaq:ARWR) announced today that R. Bruce Stewart, Chairman, has been selected to present at Global Crown Capital’s Nanotechnology Investment Conference in San Francisco on Monday, October 30, 2006. Mr. Stewart’s presentation, entitled “Nanotech: Here and Now,” will highlight Arrowhead’s progress in commercializing nanotechnology applications in the areas of nanomedicine and nanoelectronics. Mr. Stewart will also describe how Arrowhead’s unique business model is addressing opportunities in nanotechnology.
A life-long entrepreneur, Mr. Stewart has started and funded more than eighteen companies and has taken several of them to the public markets. His capital market experience spans thirty years and he has raised substantial capital for both public and private companies. He is known for his success in building value for shareholders and innovating novel strategies in corporate finance. Prior to founding Arrowhead Research, Mr. Stewart founded Acacia Research Corporation, which he took public in 1995. During Mr. Stewart’s eight-year tenure, Acacia built a portfolio of subsidiary companies operating in the areas of biotechnology, media technology licensing, direct marketing and early internet applications, and reached a market cap of close to $1 billion. Mr. Stewart gained much of his knowledge and experience in corporate finance as President of Annandale Securities from 1977 to 1992, an investment banking firm and registered broker dealer.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.